

Research Article



SOI: <http://s-o-i.org/1.15/ijarbs-2016-3-2-4>

**Psychosocial problems associated with multitransfusion of thalassemic patients in Diyala province, Iraq.**

**Dr. Kareem Assi Obaid MD CABP**

Pediatrics Department, Medical College, Diyala University, Iraq

\*Corresponding author: [karimalhamdany@yahoo.com](mailto:karimalhamdany@yahoo.com)

**Abstract**

**Background:** Beta-thalassemia major is a chronic disorder of blood, having an extensive impact on the affected child. It involves lifelong therapeutic regime, with repeated blood transfusions. With improved life expectancy, due to improved medical management psychosocial aspects of thalassemia are gaining importance. **Objective:** Thalassemia is a chronic disease that manifests early in life that it leads to psychological and social problems for parents. Focused on parents to assess the impact of their child's disease and to assess the behavioral problems in multi-transfused thalassemic children and psychosocial factors affecting them. **Materials and Methods:** This is a cross sectional study conducted in the Thalassemia Centre of Al-batool teaching hospital, Diyala, Iraq. The study was carried out from August 2013 to April 2014, parents and their patients with established diagnosis of thalassemia of their child and the child was registered with the thalassemia centre for regular blood transfusion. **Results:** The CBCL total scores were high in 32% patients, indicating the presence of behavioral problems. Higher CBCL scores were found in children of older age group, those with poor school performance, whose mothers' education was more than eighth standard, had history of death of thalassemic relative in family, greater duration of diagnosed illness, poor pre-transfusion hemoglobin level, and who had longer periods of school absenteeism. **Conclusions:** Behavioral problems are common in multi-transfused thalassemic children. Early diagnosis and intervention of behavioral problems in these children would make them cope with thalassemia better.

**Keywords:** Behavioral problems, child behavior check list, multi-transfused thalassemia, frequent hospitalization, long-term costly care.

**Introduction**

Thalassemia is a blood disorder passed down through families (inherited) in which the body makes an abnormal form of hemoglobin. This disorder results in excessive destruction of red blood cells, and there is no effective treatment. Patients require lifelong blood transfusion, usually started within 6 to 12 months of birth of patient, which on other hand has its own complications. It is a chronic disease that manifests early in life that it leads to psychological and social problems for parents. We focused on parents to assess the impact of their child's disease.

Worldwide, thalassemia poses a serious public health problem due to the high prevalence, it extends from

the Mediterranean basin and parts of Africa, throughout the Middle East, the Indian Sub-continent, South-East Asia and into the Pacific Islands, with reported rates ranging from 2% to 25% [1]. Each year, 50,000 to 100,000 children die of thalassemia major in low and middle income countries, while about 7% of the world's population is a carrier of a hemoglobin disorder. [1] The more severe forms are beta-thalassemia major, which warrants regular blood transfusion at an early age, and thalassemia intermedia which presents later and requires less frequent transfusions. The aim of regular blood transfusions is to eliminate the primary complications of severe thalassemia by ameliorating anemia and suppressing

erythropoiesis. Patients are usually transfused at an early age. The chronicity and complications of thalassemia affect the quality of life of victims and parents and cause physical, psychological, and economic problems. [2] As there is no definitive cure for this disease, the majority exclusively depend on blood transfusions as a treatment option that creates a burden not only on health system but also on the affected families, who are vulnerable to, social, and psychological problems. [3, 4] Various Quality of Life (QOL) studies conducted worldwide on thalassemia indicated poor indicators for the sufferers. [5]

It is expected that these children are at high risk of developing behavioral and psychosocial problems like opposition, passiveness, anxiety, phobias and depression, which affect their self-confidence and give rise to emotions and thoughts which negatively affect their quality of life and compliance to therapy. [6] Many of the thalassaemic children experience fear related to intravenous line insertion and subcutaneous infusion pumps. Children with thalassemia in the pre-school and latency age groups are usually anxious and excessively dependent on their parents. [7] They display psychosomatic symptoms and are frequently absent from school. Thalassaemic children have more of negative self-concept when compared to their normal counterparts.[8]. Regular blood transfusions improve the overall survival of multitransfused children but despite the progress made in preventing transfusion-transmitted infections (TTIs) over the last few years, TTIs continue to be a problem in many parts of the world. [9] Blood transfusion is the main risk factor for transmitting viral hepatitis, particularly in patients with hematological diseases. [10] The TTI problem is directly proportional to the prevalence of infection in the blood donor community. [11] Patients with thalassemia commonly receive transfusions and thus, are exposed to transfusion-associated infections .Among these infections, hepatitis B and hepatitis C are the most common. [12] Hepatitis B is an important infection in patients with thalassemia and prevention and severe thalassemiias by vaccination is necessary . type of sickle cell diseases. As there are no physiological mechanisms to excrete the iron contained in transfused red cells (1 unit of blood contains approximately 200 mg of iron) the excess of iron is stored in various organs. Cardiomyopathy is the most severe complication covering more than 70% of patients. Although thalassaemic the causes of death of chelator the current reference standard iron (DFO) has been used clinically for over ) deferoxamine four decades, its effectiveness is limited by a demanding therapeutic regimen that leads to poor

compliance. Despite poor compliance, because of the inconvenience of subcutaneous infusion, DFO improved considerably the survival and quality of life since 1998 Deferiprone .of patients with thalassemia since 2005 were licensed for clinical Deferasirox and have a better compliance chelators use. The oral because of oral use, a comparable efficacy to DFO in iron excretion and probably a better penetration to myocardial cells. Considerable increase in iron excretion was documented with combination therapy. The proper use of the three chelators will improve the prevention and treatment of iron overload, it will reduce complications, and improve survival and quality of life of transfused patients. [13,14]

## **Materials and Methods**

This is a cross sectional Study conducted in the Thalassemia Centre of Al-batool teaching hospital, Diyala, Iraq. The study was carried out from August 2013 to April 2014. All Parents who brought their children for blood transfusion those parents who fulfilled the inclusion criteria were included in the study. The criteria were: a) established diagnosis of thalassemia of their child and the child was registered with the Thalassemia centre for regular blood transfusion, b) parents who provided consent for the study.Data was collected on a questionnaire comprising 25 questions that was self designed to assess the psychological and social problems, (name, date of diagnosis, family history of thalassemia, family death, consanguinity, no(frequency) of transfusions, volume of transfusions, chelation type, chronic illness, no.of affected siblings, bone marrow aspiration, parents education, serum ferritin, liver function test, HBsAG and Anti HCV, hepatosplenomegaly, bone changes, social problems, financial problems, weight, height, OFC, school performance, behavioral problems, drug reaction)

## **Results**

There was a preponderance of males in parenteral treatment group and females in oral treatment group (Table 1) and overall there were 56 males haematologic among the 100 patients in the study. Apart from 5 individuals with b-thalassemia were not receive chelation therapy, all other patients had oral or parenteral chelation therapy . During the 9 months had taken 100 case as sample of thalassaemic patients in Diyala city to assess the psychosocial problems and the results in (table 4) explain the social problems and behavioral problems more common in parenteral treatment while the school absence higher in oral chelation treatment group . In (table 1) the demographic data of the patients. table 2 explain the comorbidity associated with both treatment group.

**Table 1: Demographic data of the patients participating to the study.**

XXXXXXXXXXXXX	Oral Chelation 27 case	Parenteral Chelation 68 case
Gender		
Male	13 (0.48%)	40 (58%)
Female	14 (0.51%)	28 (41%)
Parents Education		
NON	2 (0.07%)	10 (0.14%)
Primary	12 (0.44%)	22 (0.32%)
Secondary	7 (0.25%)	31 (0.45%)
High	6 (0.22%)	5 (0.07%)
education		
Physical activity		
Normal	13 (0.48%)	36 (0.52%)
low	12 (0.26%)	32 (0.47%)

**Table 2; Co-morbidities associated with the disease in both modes of Chelation.**

XXXXXXXXXXXXX	Oral Chelation 27 case	Parenteral Chelation 68 case
Bone changes	12 (44%)	47 (69%)
Liver	9 (33%)	16 (23%)
Spleen	13 (48%)	57 (83%)
Hepatitis(type B,C)	2 (7%)	6 (8%)
Anxiety	5(18%)	20(29%)
Depressive symptoms	2(7%)	11(16%)
depressive mood	4(14%)	22(32%)
Other chronic disease	2 (7%)	6 (8%)
Bone aspiration	4 (14%)	10 (14%)

**Table 3 Disease characteristics**

XXXXXXXXXXXXX	Oral Chelation 27 case	Parenteral Chelation 68 case
Age of onset,		
At or before 1st year	20 (74%)	50(73%)
After 1st year	7 (25%)	18(26%)
Frequency of transfusion,		
Monthly	14 (51%)	39 (57%)
Less than month	11 (40%)	29 (42%)
More than month	2 (7%)	1 (0.14%)

**Table 4; Oral versus Parenteral Chelation morbidities**

	Oral Chelation 27case	Parenteral Chelation 68 case
Social problems	6 (0.22%)	27 (0.39%)
School absence	19 (0.7%)	29 (0.42%)
Financial problems	12 (0.44%)	30 (0.44%)
Behavioral problems	12 (0.26%)	32 (0.47%)

## Discussion

Over the past 25 years have shown that prevalence of behavioral disorders among thalassemic children ranged from 23 to 80%, [15-16] and these psychological disturbances adversely affect compliance to treatment in thalassemia. [17] In this study, it was found that 32% of thalassemic children This study had clinically abnormal CBCL total scores. have been showing people with thalassemia major scored significantly lower on all the health measured as compared with the general population, an improvement in all mental dimensions was observed. Cakaloz et al. reported that psychopathology was common in patients with thalassemia [20]. Similarly, Ghanizadeh et al. reported that most commonly observed psychopathologies were major depression and anxiety in patients with thalassemia [21]. This study reported that there was depressive mood in 22(32%) of those with parenteral chelation compared to 4 (14%) from those with oral Chelation. Cakaloz et al. detected depressive disorder in 15% and anxiety disorder in 30% of the children with thalassemia [20]. In a study by Aydınok et al., frequency of depressive disorder was reported as 23% in patients with thalassemia [19]. This study, depression symptoms were detected in 2(7%) of those with oral Chelation while 11(16%) of those with parenteral Chelation had this problem, while anxiety symptoms at varying severity were detected in 5(18%) of patients with thalassemia with oral Chelation compared to 20(29%) among those with parental chelation.

In a study on patients with thalassemia major or intermedia, Azarkeivan A et al. reported that depression negatively affected quality of life in both physical and mental manner. Authors demonstrated that anxiety had negative effects on quality of life in mental manner [22]. Hajibei B et al. evaluated effects of anxiety and depression on sleep quality and quality of life in patients with thalassemia and found that these psychopathologies negatively affected sleep quality and quality of life independent from somatic complaints. This study detected that there was a decrease in physical and mental quality of life in thalassemia patients with depressive symptoms. Moreover, both physical and mental quality of life decreased in BTM patients with anxiety symptoms. In regression analysis, it was seen that physical and mental quality of life was influenced from presence of depression but not anxiety in BTM patients [22].

## Conclusion

In conclusion, thalassemia leads an increase in the frequency of depression and anxiety in both patients

and their caregivers. This increase results in negative effects on physical and mental quality of life in patients and their caregivers. In particular, depression plays role in these negative effects independently from anxiety.

Patients with thalassemia expose to intensive and serious medical therapies and their complications lifelong. Thus, psychological status of these patients has important effects on their quality of life.

## References

- 1-WHO-TIF Meeting. Management of hemoglobin disorders. Report of a joint WHOTI Fmeeting; Nicosia, Cyprus. Geneva: WHO; 2008.
- 2-. Weatherall DJ, Clegg JB: Inherited hemoglobin disorders: an increasing global health problem. Bull World Health Organ 2001, 78:704–712.
- 3-Shaligram D, Girimaji SC, Chaturvedi SK: Psychological problems a quality of life in children with thalassemia. Indian J Pediatr 2007 74:727–730.
- 4-Bandyopadhyay B, Nandi S, Mitra K, Mandal PK, Mukhopadhyay S, Biswas AB: A comparative study on perceptions and practices among parents of thalassemic children attending two different institutions. Indian J Comm Med 2003, 28:128–132.
- 5-Mikelli A, Tsiantis J: Brief Report: Depressive symptoms and quality of life in adolescents with beta-thalassemia. J Adolesc 2004, 27:213–216
- 6-Aydin B, Yaprak I, Akarsu D, Okten N, Ulgen M. Psychosocial aspects and psychiatric disorders in children with thalassemia major. Acta Pediatr Jpn. 1997;39:354–7. [PubMed]
- 7-Khurana A, Katyal S, Marwaha RK. Psychosocial burden in Thalassemia. Indian J Pediatr. 2006;73:877–80. [PubMed]
- 8- Moorjani JD, Issac C. Neurotic manifestations in adolescents with thalassemia major. Indian J Pediatr. 2006;73:603–7. [PubMed]
- 9-Lopez L, Lopez P, Arago A, Rodriguez I, Lopez J, Lima E, et al. Risk factors for hepatitis B and C in multi-transfused patients in Uruguay. J Clin Virol. 2005;34 (Suppl 2):S69-74.
- 10-El-Raziky MS, El-Hawary M, El-Koofy N, Okasha S, Kotb M, Salama K et al. Hepatitis C virus infection in Egyptian children: single centre experience. J Viral Hepat. 2004;11(5):471-6.
- 11-Jain R, Jose B, Coshic P, Agarwal R, Deorari AK. Blood and blood component therapy in neonates. Indian J Pediatr. 2008;75(5):489-95.

- 12-Feld J, Lee JY, Locarnini S. New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. *Hepatology*. 2003;38(3):545-53.
- 13- Modell B. Total management of thalassemia. *Arch Dis Child*. 1977;52:489–500. [PMC free article] [PubMed]
- 14-Modell B, Berdoukas V. *The Clinical Approach to Thalassemia*. London: Grune & Stratton; 1984
- 15- Sherman M, Koch D, Giardina P, Seigel P, Siegel R, Shapiro T. Thalassaemic children's understanding of illness: A study of cognitive and emotional factors. *Anns N Y Acad Sci*. 1985;445:327–36
- 16- Pradhan PV, Shah H, Rao P, Ashturkar D, Ghasias P. Psychopathology and self esteem in chronic illness. *Indian J Pediatr*. 2003;70:135–8.
- 17- Beratis S. Psychosocial status in preadolescent children with B thalassemia. *J Psychosom Res*. 1993;37:271–9.
- 18- Canatan D, Ratip S, Kaptan S, Cosan R. Psychosocial burden of beta-Thalassemia major in Antalya, South Turkey. *Soc Sci Med*. 2003;56:815–9.
- 19- Shaligram D, Girimaji SC, Chaturvedi SK. Psychological problems and quality of life in children with Thalassemia. *Indian J pediatr*. 2007;74:727–30.
20. Cakaloz B, Cakaloz I, Polat A, Inan M, Oguzhanoglu NK. Psychopathology in thalassemia major. *Pediatr Int*. 2009;51:825–828.
21. Ghanizadeh A, Khajavian S, Ashkani H. Prevalence of psychiatric disorders, depression, and suicidal behavior in child and adolescent with thalassemia major. *J Pediatr Hematol Oncol*. 2006;28:781–784.
22. Azarkeivan A, Hajibeigi B, Alavian SM, Lankarani MM, Assari S. Associates of poor physical and mental health-related quality of life in beta thalassemia-major/intermedia. *J Res Med Sci*. 2009;14:349–355.

<b>Access this Article in Online</b>	
	<b>Website:</b> <a href="http://www.ijarbs.com">www.ijarbs.com</a>
	<b>Subject:</b> <b>Medical Sciences</b>
<b>Quick Response Code</b>	

**How to cite this article:**

**Kareem Assi Obaid. (2016). Psychosocial problems associated with multitransfusion of thalassaemic patients in Diyala province, Iraq. *Int. J. Adv. Res. Biol. Sci.* 3(2): 12-16.**